Percutaneous closure versus surgical of the perimembranous interventricular communication

Original title: Transcatheter versus Surgical Closure of Perimembranous Ventricular Septal Defects in Children: A Randomized Controlled Trial. Reference: Jian Yang et al. J Am Coll Cardiol. 2014; Epub ahead of print.

 

The ventricular septal defect (VSD) is the most common congenital heart disease, and perimembranous being the most common variant. In countries like USA surgery is considered the treatment of choice for this variant of VSD since the initial studies on percutaneous closure had a high chance (2.9 to 5.7 %) of complete atrioventricular block. However in developing countries like China and India, percutaneous closure has shown low mortality and morbidity using specially modified nitinol devices for perimembranous variant.

Between January 2009 and July 2010, 465 patients aged 3 to 12 years diagnosed with perimembranous VSD were evaluated clinically and with transthoracic echocardiogram in 3 high-volume centers of China, finally leaving 229 who met the criteria for inclusion and exclusion be randomized to surgery (n = 115) and percutaneous closure (n = 114). Patients randomized to percutaneous closure received the device Shanghai pmVSD occluder (Lepu Medical Technology Co, Ltd, Beijing, China), designed especially for perimembranous VSD. In the case of surgery,direct suture or Dacron or pericardial patch was used, depending on the size.

Mean age was 5.8 ± 2.4 years in the surgical group versus 5.5 ± 2.6 in the percutaneous group (p = 0.398). There were no differences in other baseline characteristics including the size of the defect.

No deaths, strokes or other major complications were observed in-hospital. There were 32 (32.3 %) minor complications in the surgical group versus 7 (6.9 %) in the percutaneous group (p < 0.001). After two years, no deaths were reported, neurological deficits, thrombus embolism, endocarditis, or complete atrioventricular blocks. The end diastolic volume assessed by echocardiography (Z score) decreased significantly in both groups. 

Conclusion

Both surgical and percutaneous closures were effective and showed excellent mid-term results for treating perimembranous ventricular septal defects. In this paper, percutaneous closure had fewer incidences of myocardial injury, transfusion requirements, hospital stay, economic costs, and recovery time.

Editorial comment

Infundibular and tubular types of Perimembranous VSD were technically more simple to treat percutaneously  than the aneurysmal type, if so far possible, may need more care.

SOLACI.ORG

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...